XtalPi Inc.

About XtalPi Inc.

XtalPi is a pharmaceutical technology company that utilizes computational modeling and machine learning to predict drug interactions and properties, followed by experimental validation in wet labs. This approach reduces the time and cost associated with traditional drug discovery processes, enabling faster development of effective therapeutics.

```xml <problem> Traditional drug discovery and development processes are time-consuming and expensive, often involving extensive trial-and-error experimentation to identify promising drug candidates and predict their properties. This can lead to delays in bringing effective therapeutics to market and increased costs for pharmaceutical companies. </problem> <solution> XtalPi offers an AI-powered drug discovery platform that integrates computational modeling, machine learning, and automation to accelerate the identification and development of novel therapeutics. The platform leverages AI, quantum mechanics, and robotics to predict drug interactions, optimize lead compounds, and streamline R&D processes. By combining computational predictions with experimental validation, XtalPi reduces the time and cost associated with traditional drug discovery, enabling faster development of effective treatments. The platform offers solutions spanning digital chemistry, drug discovery, and solid-state research. </solution> <features> - XInsight: Patent extraction tool for identifying relevant prior art and competitive landscape. - XFEP: High-accuracy free energy calculation tool for predicting binding affinities and optimizing drug candidates. - XMolGen: Generative chemistry tool for exploring novel chemical space and designing new molecules. - Automation-aided chemical synthesis for rapid and efficient production of drug candidates. - XtalGazer: Software for solid-state research and crystal structure prediction. - Hit discovery and lead optimization services leveraging AI and automation. - Biology capabilities for target validation and mechanism-of-action studies. </features> <target_audience> XtalPi's primary customers are pharmaceutical companies and research institutions seeking to accelerate their drug discovery and development efforts, reduce costs, and improve the efficiency of their R&D processes. </target_audience> ```

What does XtalPi Inc. do?

XtalPi is a pharmaceutical technology company that utilizes computational modeling and machine learning to predict drug interactions and properties, followed by experimental validation in wet labs. This approach reduces the time and cost associated with traditional drug discovery processes, enabling faster development of effective therapeutics.

Where is XtalPi Inc. located?

XtalPi Inc. is based in Cambridge, United Kingdom.

When was XtalPi Inc. founded?

XtalPi Inc. was founded in 2015.

How much funding has XtalPi Inc. raised?

XtalPi Inc. has raised $268.6M.

Who founded XtalPi Inc.?

XtalPi Inc. was founded by Lipeng Lai.

  • Lipeng Lai - Co-founder
Location
Cambridge, United Kingdom
Founded
2015
Funding
$268.6M
Employees
240 employees
Investors
5Y CapitalFreesvcSky9 CapitalZhen Fund
XI

XtalPi Inc.

XtalPi is a pharmaceutical technology company that utilizes computational modeling and machine learning to predict drug interactions and properties, followed by experimental validation in wet labs. This approach reduces the time and cost associated with traditional drug discovery processes, enabling faster development of effective therapeutics.

Cambridge, United KingdomFounded 20152407K+ followers10/10 TractionRelative Traction Score based on online presence metrics compared to companies in the same age group.
Updated 2 months ago

Funding

$268.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Traditional drug discovery and development processes are time-consuming and expensive, often involving extensive trial-and-error experimentation to identify promising drug candidates and predict their properties. This can lead to delays in bringing effective therapeutics to market and increased costs for pharmaceutical companies.

Solution

XtalPi offers an AI-powered drug discovery platform that integrates computational modeling, machine learning, and automation to accelerate the identification and development of novel therapeutics. The platform leverages AI, quantum mechanics, and robotics to predict drug interactions, optimize lead compounds, and streamline R&D processes. By combining computational predictions with experimental validation, XtalPi reduces the time and cost associated with traditional drug discovery, enabling faster development of effective treatments. The platform offers solutions spanning digital chemistry, drug discovery, and solid-state research.

Target Audience

XtalPi's primary customers are pharmaceutical companies and research institutions seeking to accelerate their drug discovery and development efforts, reduce costs, and improve the efficiency of their R&D processes.

Features

  • XInsight: Patent extraction tool for identifying relevant prior art and competitive landscape.
  • XFEP: High-accuracy free energy calculation tool for predicting binding affinities and optimizing drug candidates.
  • XMolGen: Generative chemistry tool for exploring novel chemical space and designing new molecules.
  • Automation-aided chemical synthesis for rapid and efficient production of drug candidates.
  • XtalGazer: Software for solid-state research and crystal structure prediction.
  • Hit discovery and lead optimization services leveraging AI and automation.
  • Biology capabilities for target validation and mechanism-of-action studies.
1
This profile is AI-generated and may contain inaccuracies.